Newsroom
Cutting-Edge Research. Translational Science.
Scientific Publications
Functional characterization of tumor-specific CRISPR-directed gene editing as a combinatorial therapy for the treatment of solid tumors
Authors: Banas KH, Bialk PA, Rivera-Torres N, Owens, K, Reiner, TN, Pisarcik, KM Haas, N, Gielda, E, Khan, K, Narra, KP, Kmiec EBJournal: Molecular Therapy Oncology, December 2025
CRISPR gene editing: Can we make cancer cells easier to kill?
Author: Eric B. Kmiec
Journal: Research Outreach (Page 62) 2024
CRISPR-Directed Gene Editing as a Method to Reduce Chemoresistance in Lung Cancer Cells
Authors: Rivera-Torres N, Bialk P, Kmiec EB
Book: Cancer Systems and Integrative Biology, 2023
Authors: Banas K, Modarai S, Rivera-Torres N, Yoo B-C, Bialk P, Barrett C, Batish M, Kmiec EB
Journal: Gene Therapy, 2022Potential Inequities in New Medical Technologies
Authors: Kmiec EB, Marron J
Journal: Scientific American, 2020Authors: Banas K, Rivera-Torres N, Bialk P, Yoo BC, Kmiec EB
Journal: Molecular Cancer Research, 2020Authors: Bialk P, Wang Y, Banas K, Kmiec EB
Journal: Molecular Therapy Oncolytics, 2018
Latest News
CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment
Publication: Business WireCorriXR Therapeutics Announces Publication of Preclinical Data Demonstrating Potential of CRISPR-Directed Gene Editing to Overcome Drug Resistance in Solid Tumors
Publication: Business WireNew C-suite hire turns CorriXR into ‘Spark Junior’ as $20M Series A launches
Publication: Philadelphia Business Journal
CorriXR Therapeutics Secures $1M Investment from State of Delaware
Publication: Business Wire
CorriXR Therapeutics Appoints Jan Case as Chief Operating Officer
Publication: Business Wire
4 companies to watch in the accelerating gene editing race
Publication: PharmaVoice
CorriXR Therapeutics Names Eric Kmiec Chief Executive Officer
Publication: Business Wire
CorriXR Therapeutics Appoints Jill Castilla to Its Board of Directors
Publication: Business Wire
Precision Medicine in Delaware: Working to treat every body according to its genetic makeup
Publication: Delaware Business Times
RealLIST Connectors 2024: Meet 20 of the most impactful leaders in Delaware’s innovation scene
Publication: Technical.ly
CorriXR: How This Company Is Using CRISPR/Cas Gene Editing To Develop New Medicines
Publication: Pulse 2.0
RealLIST Startups 2024: Delaware’s most promising early-stage companies
Publication: Technical.ly
Contact Us
Reach out to discuss partnerships to advance our technology.